KS-TREVIPAY
16.1.2024 13:01:34 CET | Business Wire | Press release
TreviPay, the most-trusted B2B payments and invoicing network, today announced the launch of its Universal Acceptance solution to expand supplier access to and faster implementation of TreviPay’s payments and invoicing technology, in partnership with Mastercard. Suppliers who accept Mastercard will be able to extend net terms, or trade credit financing, and SKU-level invoicing to business buyers through TreviPay’s Universal Acceptance solution using Mastercard’s commercial card payment capabilities.
Research1 commissioned by TreviPay unveiled the top three pain points of global business buyers are inefficient processes, incorrect invoicing and slow onboarding. The same research ranked trade credit as a leading payment option preferred by business buyers. With minimal integration required, TreviPay’s Universal Acceptance solution enables suppliers who are already accepting credit cards to quickly and easily offer net-terms financing to their qualified buyers, while taking on no credit risk. TreviPay automates the buyer onboarding, financing and accounts receivable process to drive payment efficiencies and streamline time-consuming back-office operations.
“TreviPay’s technology was developed to eliminate the complexities of B2B purchasing and create a consumer-like purchasing experience while still catering to the needs and requirements of business buyers,” said Brandon Spear, CEO of TreviPay. “Joining forces with Mastercard to launch the Universal Acceptance solution marks an industry milestone in expanding access to TreviPay’s solution, a leading B2B payment method of corporate sellers and their buyers globally. Together we are revolutionizing how businesses can transact by bringing flexible extended payment terms to more buyers.”
With TreviPay leveraging Mastercard’s global acceptance network and commercial card payment capabilities, suppliers are able to provide approved buyers with a net-terms card for purchasing, offering the checkout convenience of a credit card, as well as the auditability and purchase controls of trade credit. The TreviPay platform then automatically delivers invoices directly to the merchant’s buyer, eliminating the costs associated with chasing outstanding or late payments, assuming all risk associated with collection and guaranteeing settlement to the merchant upfront.
“Mastercard is committed to building industry partnerships that help suppliers better meet the purchasing needs of their B2B customers and drive loyalty,” said Rebecca Meeker, Senior Vice President, Global Partnerships and Segments, Mastercard. “With a shared vision to bring consumer-grade convenience to B2B transactions, we are proud to deepen our collaboration with TreviPay as they facilitate variable financing options, seamless invoice reconciliation and faster settlement when using cards on our network.”
With the addition of the Universal Acceptance solution, the TreviPay platform can now be implemented for suppliers in two ways: the original API integration of the platform directly into the seller’s point of acceptance, or without API integration, by instead leveraging Mastercard’s global acceptance network.
This announcement comes shortly after TreviPay’s launch of Financial Partner Gateway, a new suite of APIs for financial institutions looking to expand commercial offerings. The Universal Acceptance solution complements this offering as another way TreviPay is expanding its global footprint and optimizing the payment experience for suppliers.
Read more about TreviPay’s Universal Acceptance solution.
1 The study was conducted by Murphy Research on behalf of TreviPay from May 17 to June 2, 2023. The results are based on a comprehensive review of 300 global B2B buyers.
About TreviPay
At TreviPay, we believe loyalty begins at the payment. By understanding the diverse and unique requirements of B2B sellers, TreviPay’s global B2B payments and invoicing network enables enterprises to provide payments choice and convenience, open new markets and automate accounts receivables. With more than four decades of experience, TreviPay serves leaders looking to build loyalty while driving efficiency and embracing new digital channels, especially in industries with large distribution networks such as manufacturing, retail, and transportation. For more information, visit trevipay.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116535144/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom